FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166205752> ?p ?o ?g. }

• W3166205752 endingPage "2996" @default.
• W3166205752 startingPage "2987" @default.
• W3166205752 abstract "Although several randomized clinical trials performed in children 6 years and older with Omalizumab as add-on therapy have reported improvements in diverse clinical outcomes, the evidence regarding its cost effectiveness is not sufficient, especially in less-affluent countries, where the clinical and economic burden of the disease is the greatest. The aim of the present study was to perform a cost-utility analysis of adding omalizumab to standard treatment for treating pediatric patients with uncontrolled severe allergic asthma in Colombia, a middle-income country (MIC).A Markov-type model was developed to estimate costs and health outcomes of a simulated cohort of pediatric patients with persistent asthma treated over a 5-year period. The effectiveness data and transition probabilities were obtained from various sources, including systematic reviews with meta-analysis. Cost data were obtained from official databases provided by the Colombian Ministry of Health. The study was carried out from the perspective of the national healthcare system in Colombia. The main outcome was the variable ''quality-adjusted life-years'' (QALYs).For the base-case analysis, the cost-utility analysis showed that compared with the standard treatment strategy, the omalizumab strategy involved higher costs (US$72,142.3 vs. $20,243.4 average cost per patient) and greater gain in QALYs (0.8718 vs. 0.8222 QALYs on average per patient). The incremental cost-utility ratio (ICUR) of omalizumab compared with standard treatment was US$82,748.1 per QALY CONCLUSIONS: This study shows that in Colombia, an MIC, compared with standard treatment, omalizumab is not a cost-effective strategy for treating pediatric patients with uncontrolled severe allergic asthma." @default.
• W3166205752 created "2021-06-22" @default.
• W3166205752 creator A5019801669 @default.
• W3166205752 creator A5021449955 @default.
• W3166205752 creator A5081829056 @default.
• W3166205752 date "2021-06-24" @default.
• W3166205752 modified "2023-10-18" @default.
• W3166205752 title "Cost‐utility of omalizumab for the treatment of uncontrolled moderate‐to‐severe persistent pediatric allergic asthma in a middle‐income country" @default.
• W3166205752 cites W1898930241 @default.
• W3166205752 cites W1928142138 @default.
• W3166205752 cites W1964494343 @default.
• W3166205752 cites W1974599886 @default.
• W3166205752 cites W1982386486 @default.
• W3166205752 cites W1999515199 @default.
• W3166205752 cites W2008943292 @default.
• W3166205752 cites W2019157537 @default.
• W3166205752 cites W2032689844 @default.
• W3166205752 cites W2065104775 @default.
• W3166205752 cites W2071252658 @default.
• W3166205752 cites W2073166736 @default.
• W3166205752 cites W2094829202 @default.
• W3166205752 cites W2095754126 @default.
• W3166205752 cites W2101831231 @default.
• W3166205752 cites W2112177979 @default.
• W3166205752 cites W2122664355 @default.
• W3166205752 cites W2135058166 @default.
• W3166205752 cites W2141896850 @default.
• W3166205752 cites W2164548578 @default.
• W3166205752 cites W2283484466 @default.
• W3166205752 cites W2390129378 @default.
• W3166205752 cites W2741181945 @default.
• W3166205752 cites W2790637078 @default.
• W3166205752 cites W2799887732 @default.
• W3166205752 cites W2883822660 @default.
• W3166205752 cites W2889537082 @default.
• W3166205752 cites W2892083615 @default.
• W3166205752 cites W2902499139 @default.
• W3166205752 cites W2914302947 @default.
• W3166205752 cites W2923222698 @default.
• W3166205752 cites W2946995148 @default.
• W3166205752 cites W2979874126 @default.
• W3166205752 cites W3004056291 @default.
• W3166205752 cites W3039011814 @default.
• W3166205752 doi "https://doi.org/10.1002/ppul.25541" @default.
• W3166205752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34143576" @default.
• W3166205752 hasPublicationYear "2021" @default.
• W3166205752 type Work @default.
• W3166205752 sameAs 3166205752 @default.
• W3166205752 citedByCount "8" @default.
• W3166205752 countsByYear W31662057522022 @default.
• W3166205752 countsByYear W31662057522023 @default.
• W3166205752 crossrefType "journal-article" @default.
• W3166205752 hasAuthorship W3166205752A5019801669 @default.
• W3166205752 hasAuthorship W3166205752A5021449955 @default.
• W3166205752 hasAuthorship W3166205752A5081829056 @default.
• W3166205752 hasConcept C112930515 @default.
• W3166205752 hasConcept C126322002 @default.
• W3166205752 hasConcept C127454912 @default.
• W3166205752 hasConcept C141105273 @default.
• W3166205752 hasConcept C142724271 @default.
• W3166205752 hasConcept C159654299 @default.
• W3166205752 hasConcept C160735492 @default.
• W3166205752 hasConcept C162324750 @default.
• W3166205752 hasConcept C177713679 @default.
• W3166205752 hasConcept C184834754 @default.
• W3166205752 hasConcept C187212893 @default.
• W3166205752 hasConcept C18903297 @default.
• W3166205752 hasConcept C203014093 @default.
• W3166205752 hasConcept C2776042228 @default.
• W3166205752 hasConcept C2776125615 @default.
• W3166205752 hasConcept C2778564945 @default.
• W3166205752 hasConcept C3019080777 @default.
• W3166205752 hasConcept C50522688 @default.
• W3166205752 hasConcept C535046627 @default.
• W3166205752 hasConcept C64332521 @default.
• W3166205752 hasConcept C71924100 @default.
• W3166205752 hasConcept C72563966 @default.
• W3166205752 hasConcept C86803240 @default.
• W3166205752 hasConceptScore W3166205752C112930515 @default.
• W3166205752 hasConceptScore W3166205752C126322002 @default.
• W3166205752 hasConceptScore W3166205752C127454912 @default.
• W3166205752 hasConceptScore W3166205752C141105273 @default.
• W3166205752 hasConceptScore W3166205752C142724271 @default.
• W3166205752 hasConceptScore W3166205752C159654299 @default.
• W3166205752 hasConceptScore W3166205752C160735492 @default.
• W3166205752 hasConceptScore W3166205752C162324750 @default.
• W3166205752 hasConceptScore W3166205752C177713679 @default.
• W3166205752 hasConceptScore W3166205752C184834754 @default.
• W3166205752 hasConceptScore W3166205752C187212893 @default.
• W3166205752 hasConceptScore W3166205752C18903297 @default.
• W3166205752 hasConceptScore W3166205752C203014093 @default.
• W3166205752 hasConceptScore W3166205752C2776042228 @default.
• W3166205752 hasConceptScore W3166205752C2776125615 @default.
• W3166205752 hasConceptScore W3166205752C2778564945 @default.
• W3166205752 hasConceptScore W3166205752C3019080777 @default.
• W3166205752 hasConceptScore W3166205752C50522688 @default.
• W3166205752 hasConceptScore W3166205752C535046627 @default.
• W3166205752 hasConceptScore W3166205752C64332521 @default.

• next